Influenza economic burden among potential target risk groups for immunization in South Africa, 2013-2015
Copyright © 2020 Elsevier Ltd. All rights reserved..
BACKGROUND: Data on influenza economic burden in risk groups for severe influenza are important to guide targeted influenza immunization, especially in resource-limited settings. However, this information is limited in low- and middle-income countries.
METHODS: We estimated the cost (from a health system and societal perspective) and years of life lost (YLL) for influenza-associated illness in South Africa during 2013-2015 among (i) children aged 6-59 months, (ii) individuals aged 5-64 years with HIV, pulmonary tuberculosis (PTB) and selected underlying medical conditions (UMC), separately, (iii) pregnant women and (iv) individuals aged ≥65 years, using publicly available data and data collected through laboratory-confirmed influenza surveillance and costing studies. All costs were expressed in 2015 prices using the South Africa all-items Consumer Price Index.
RESULTS: During 2013-2015, the mean annual cost of influenza-associated illness among the selected risk groups accounted for 52.1% ($140.9/$270.5 million) of the total influenza-associated illness cost (for the entire population of South Africa), 45.2% ($52.2/$115.5 million) of non-medically attended illness costs, 43.3% ($46.7/$107.9 million) of medically-attended mild illness costs and 89.3% ($42.0/$47.1 million) of medically-attended severe illness costs. The YLL among the selected risk groups accounted for 86.0% (262,069 /304,867 years) of the total YLL due to influenza-associated death.
CONCLUSION: In South Africa, individuals in risk groups for severe influenza accounted for approximately half of the total influenza-associated illness cost but most of the cost of influenza-associated medically attended severe illness and YLL. This study provides the foundation for future studies on the cost-effectiveness of influenza immunization among risk groups.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Vaccine - 38(2020), 45 vom: 21. Okt., Seite 7007-7014 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tempia, Stefano [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Economic burden |
|---|
| Anmerkungen: |
Date Completed 27.04.2021 Date Revised 27.04.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.vaccine.2020.09.033 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM315509228 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM315509228 | ||
| 003 | DE-627 | ||
| 005 | 20231225155054.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.vaccine.2020.09.033 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1051.xml |
| 035 | |a (DE-627)NLM315509228 | ||
| 035 | |a (NLM)32980198 | ||
| 035 | |a (PII)S0264-410X(20)31193-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tempia, Stefano |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Influenza economic burden among potential target risk groups for immunization in South Africa, 2013-2015 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.04.2021 | ||
| 500 | |a Date Revised 27.04.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Ltd. All rights reserved. | ||
| 520 | |a BACKGROUND: Data on influenza economic burden in risk groups for severe influenza are important to guide targeted influenza immunization, especially in resource-limited settings. However, this information is limited in low- and middle-income countries | ||
| 520 | |a METHODS: We estimated the cost (from a health system and societal perspective) and years of life lost (YLL) for influenza-associated illness in South Africa during 2013-2015 among (i) children aged 6-59 months, (ii) individuals aged 5-64 years with HIV, pulmonary tuberculosis (PTB) and selected underlying medical conditions (UMC), separately, (iii) pregnant women and (iv) individuals aged ≥65 years, using publicly available data and data collected through laboratory-confirmed influenza surveillance and costing studies. All costs were expressed in 2015 prices using the South Africa all-items Consumer Price Index | ||
| 520 | |a RESULTS: During 2013-2015, the mean annual cost of influenza-associated illness among the selected risk groups accounted for 52.1% ($140.9/$270.5 million) of the total influenza-associated illness cost (for the entire population of South Africa), 45.2% ($52.2/$115.5 million) of non-medically attended illness costs, 43.3% ($46.7/$107.9 million) of medically-attended mild illness costs and 89.3% ($42.0/$47.1 million) of medically-attended severe illness costs. The YLL among the selected risk groups accounted for 86.0% (262,069 /304,867 years) of the total YLL due to influenza-associated death | ||
| 520 | |a CONCLUSION: In South Africa, individuals in risk groups for severe influenza accounted for approximately half of the total influenza-associated illness cost but most of the cost of influenza-associated medically attended severe illness and YLL. This study provides the foundation for future studies on the cost-effectiveness of influenza immunization among risk groups | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, U.S. Gov't, P.H.S. | |
| 650 | 4 | |a Economic burden | |
| 650 | 4 | |a Influenza | |
| 650 | 4 | |a Risk groups | |
| 650 | 4 | |a South Africa | |
| 650 | 4 | |a Years of life lost | |
| 700 | 1 | |a Moyes, Jocelyn |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen, Adam L |e verfasserin |4 aut | |
| 700 | 1 | |a Walaza, Sibongile |e verfasserin |4 aut | |
| 700 | 1 | |a McMorrow, Meredith L |e verfasserin |4 aut | |
| 700 | 1 | |a Edoka, Ijeoma |e verfasserin |4 aut | |
| 700 | 1 | |a Fraser, Heather |e verfasserin |4 aut | |
| 700 | 1 | |a Treurnicht, Florette K |e verfasserin |4 aut | |
| 700 | 1 | |a Hellferscee, Orienka |e verfasserin |4 aut | |
| 700 | 1 | |a Wolter, Nicole |e verfasserin |4 aut | |
| 700 | 1 | |a von Gottberg, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a McAnerney, Johanna M |e verfasserin |4 aut | |
| 700 | 1 | |a Dawood, Halima |e verfasserin |4 aut | |
| 700 | 1 | |a Variava, Ebrahim |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen, Cheryl |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Vaccine |d 1985 |g 38(2020), 45 vom: 21. Okt., Seite 7007-7014 |w (DE-627)NLM012600105 |x 1873-2518 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2020 |g number:45 |g day:21 |g month:10 |g pages:7007-7014 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.vaccine.2020.09.033 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2020 |e 45 |b 21 |c 10 |h 7007-7014 | ||